Lung Cancer Collection (2017-2019)

The collection includes all the papers on lung cancer published by Cancer Biology & Medicine in 2017-2019.

Table of Contents

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report PDF
Ling Zhang, et al. 178-181
Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report PDF
Peng Wang, et al 183-186

Original Article

Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer PDF
Yuxiang Wang, et al 66-78
Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study PDF
Yihui Du, et al. 181-188
Attenuated plasmodium sporozoite expressing MAGE-A3 induces antigen-specific CD8+ T cell response against lung cancer in mice PDF
Dong Zhou, et al 288-298
Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data PDF
Ashley M. Hopkins, et al 341-349
EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation PDF
Yang Chen, et al. 39-51
Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer PDF
Wuhao Huang, et al 88-96
Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy PDF
Ye Tian, et al. 157-164
Knockdown of long non-coding RNA LCPAT1 inhibits autophagy in lung cancer PDF
Xiao Yu, et al. 228-237
Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway PDF
Lianmei Zhao, et al 400-414
PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs PDF
Yuchen Bai, et al. 434-442
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment PDF
Jing Wang, et al 443-451
Estimation of lung cancer burden in Australia, the Philippines, and Singapore: an evaluation of disability adjusted life years PDF
Suman Morampudi, et al. 74-82
Inhibition of IKK-NFκB pathway sensitizes lung cancer cell lines to radiation PDF
Avgi Tsolou, et al. 293-301